VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update
VolitionRx Limited to Present at Conferences in March 2021
VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock
VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts
National Taiwan University Hospital Presents Data on Nu.Q™ Assay Performance at the World Conference on Lung Cancer
VolitionRx Limited Opens its New Manufacturing Facility in Belgium
VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding
VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors
